Welcome to our dedicated page for AIKI news (Ticker: aiki), a resource for investors and traders seeking the latest updates and insights on AIKI stock.
AIkido Pharma Inc. (AIKI), a biotechnology innovator since 1967, develops targeted cancer treatments and broad-spectrum antiviral therapies through academic collaborations. This page aggregates official announcements and analysis-worthy developments for stakeholders tracking the company's progress.
Access timely updates on clinical milestones, strategic partnerships with leading research institutions, and corporate initiatives like the active share repurchase program. Key focus areas include pancreatic cancer therapies, leukemia treatments, and novel antiviral platforms addressing multiple infectious diseases.
Regularly updated content covers licensing agreements, preclinical results, financial disclosures, and market expansion efforts. Bookmark this page to efficiently monitor AIkido Pharma's evolving role in oncology and virology research without navigating multiple sources.
AIkido Pharma Inc. (Nasdaq: AIKI) reported its financial results for Q1 2021, showcasing its strongest balance sheet with approximately $102 million in cash. The company is advancing its pipeline, focusing on anti-viral compounds targeting influenza and SARS-CoV-2. Notable projects include a partnership for prostate cancer treatment with Convergent Therapeutics Inc., psychedelic research for PTSD at Mount Sinai, and a patent agreement with Silo Pharma for psilocybin research. AIkido is well-positioned for future growth while maintaining a low cash burn strategy.
AIkido Pharma Inc. (Nasdaq: AIKI) announced Dr. Rachel Yehuda's participation in a panel discussion at SXSW, focusing on the role of psilocybin in mental health care. The discussion highlighted ongoing clinical trials and the potential of psilocybin therapy, recognized as "breakthrough therapy" by the FDA, to address mental health issues such as PTSD and depression, affecting 45 million Americans. AIkido supports this research, aligning with its focus on innovative treatments for psychiatric disorders and oncology.
AIkido Pharma Inc. (Nasdaq: AIKI) announced the addition of Dr. Matthew Frieman to its Scientific Advisory Board on April 26, 2021. Dr. Frieman, an expert in coronaviruses with a focus on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), has made significant contributions to understanding viral replication. The CEO, Anthony Hayes, emphasized the strategic importance of Dr. Frieman’s expertise in advancing the company's research initiatives, particularly in the context of ongoing challenges posed by the coronavirus pandemic.
AIkido Pharma Inc. (Nasdaq: AIKI) has withdrawn its S-1 Registration Statement previously submitted to the SEC, as it had not been declared effective. No securities were sold related to the offering. CEO Anthony Hayes expressed optimism about their therapeutic drug platform, citing upcoming testing data and the company's sufficient capitalization for ongoing research. AIkido is focused on developing small-molecule anti-cancer therapeutics and a broad-spectrum antiviral platform targeting various viruses.
AIkido Pharma Inc. (Nasdaq: AIKI) announced positive results from a PSMA 617-Lu177 study conducted by a major pharmaceutical company, suggesting potential success for similar technologies AIkido is developing. CEO Anthony Hayes expressed that these findings support the Company's investment in radioligand therapies, which could offer alternatives for advanced prostate cancer treatment. Despite recent stock price declines, the Company remains confident about upcoming testing data expected in Q2 2021, reinforcing their commitment to innovation in cancer therapeutics.
AIkido Pharma Inc. (Nasdaq: AIKI) announced the acquisition of an exclusive sublicense for technology using central nervous system (CNS) homing peptides aimed at treating neuroinflammatory diseases in cancer patients. These peptides facilitate the targeted delivery of psilocybin, which has exhibited anti-inflammatory properties. CEO Anthony Hayes emphasized the potential of this technology for enhancing cancer treatment, complementing existing efforts in psilocybin research for PTSD at Mount Sinai. The company continues to develop a diverse portfolio of oncology therapies.
AIkido Pharma Inc. (Nasdaq: AIKI) announced a business update focusing on cancer and viral infection treatments. The company reported progress in preclinical studies through partnerships with educational institutions. Key initiatives include sponsoring psychedelic research for PTSD treatment and advancing antiviral drug development targeting influenza and SARS-CoV-2. AIkido raised nearly $90 million for research and has a solid cash position of approximately $25 million. Additionally, new directors and advisors were appointed to strengthen corporate governance.
AIkido Pharma Inc. (Nasdaq: AIKI) has announced its sponsorship of psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research. The research aims to explore the therapeutic potential of psychedelics for treating post-traumatic stress disorder (PTSD), particularly among veterans. The Center will conduct clinical trials using MDMA and psilocybin, gathering biological data to identify treatment outcome biomarkers. With over 8.6 million adults suffering from PTSD annually, this initiative highlights the urgent need for innovative therapies in mental health.
AIkido Pharma Inc. (Nasdaq: AIKI) announced Dr. Matt Frieman's recent appearance on the podcast This Week in Virology, where he discussed the Covid-19 pandemic as a coronavirologist. At the 42-minute mark, he emphasized the future prospects of virology, particularly AIkido's pan-viral initiative. The company is committed to developing a family of pan-viral drugs alongside industry leaders. AIkido Pharma focuses on a diverse portfolio of anti-cancer therapeutics and broad-spectrum antiviral platforms targeting multiple viruses, including SARS-CoV and Ebolavirus.
AIkido Pharma Inc. (NASDAQ: AIKI) announced its participation at the H.C. Wainwright Global Life Sciences Conference, taking place virtually on March 9-10, 2021. The company will present an updated Investor Presentation and discuss new technology, with Vice President Darrell Dotson leading the presentation. The presentation will be accessible on-demand starting at 7 a.m. ET on March 9, 2021, and available for 90 days. AIkido Pharma focuses on developing anti-cancer therapeutics and antiviral platforms through collaborations with prominent universities.
